Table 2.
Anthropometric and clinical outcomes across the intervention period.
| mRMR Group | eRMR Group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Baseline | Week 3 | Week 6 | Week 12 | n | Baseline | Week 3 | Week 6 | Week 12 | Time Effect, p | Group Effect, p | Time-by-Group Interaction, p | |
| Weight (kg) | 22 | 89.0 ± 13.6 | 87.3 ± 13.7 | 86.7 ± 13.6 | 86.0 ± 13.7 | 17 | 93.7 ± 18.7 | 92.0 ± 17.8 | 90.5 ± 17.0 | 90.7 ± 17.8 | p < 0.0005 * | p = 0.38 | p = 0.52 |
| BMI (kg/m2) | 24 | 30.4 ± 5.2 | 29.4 ± 5.2 | 23 | 31.1 ± 4.4 | 30.4 ± 4.0 | p < 0.0005 * | p = 0.53 | p = 0.57 | ||||
| WC (cm) | 23 | 109.0 ± 13.9 | 98.2 ± 11.8 | 23 | 113.2 ± 12.3 | 105.5 ± 11.1 | p < 0.0005 * | p = 0.10 | p = 0.22 | ||||
| HC (cm) | 23 | 117.2 ± 14.5 | 108.6 ± 10.4 | 23 | 117.0 ± 13.7 | 108.8 ± 8.1 | p < 0.0005 * | p = 0.99 | p = 0.92 | ||||
| WHR | 23 | 0.9 ± 0.1 | 0.9 ± 0.1 | 23 | 1.0 ± 0.1 | 1.0 ± 0.1 | p = 0.05 * | p = 0.02 * | p = 0.12 | ||||
| Body Fat (%) | 22 | 36.5 ± 9.2 | 36.7 ± 9.6 | 35.3 ± 9.5 | 36.9 ± 11.3 | 17 | 36.3 ± 7.0 | 35.3 ± 7.7 | 35.0 ± 7.2 | 35.6 ± 7.7 | |||
| Muscle Mass (kg) | 22 | 54.0 ± 11.7 | 52.7 ± 11.8 | 53.4 ± 11.4 | 51.8 ± 12.8 | 17 | 57.2 ± 13.3 | 56.9 ± 12.9 | 56.5 ± 13.3 | 56.0 ± 13.2 | p < 0.0005 * | p = 0.36 | p = 0.37 |
| BPsys (mmHg) | 23 | 124.0 ± 15.4 | 121.2 ± 14.3 | 23 | 137.8 ± 20.5 | 130.8 ± 16.2 | p < 0.0005 * | p = 0.01 * | p = 0.30 | ||||
| BPdia (mmHg) | 23 | 81.2 ± 11.7 | 77.9 ± 9.0 | 23 | 86.7 ± 9.8 | 83.8 ± 9.7 | p < 0.0005 * | p = 0.04 | p = 0.88 | ||||
Values are presented as the mean ± SD. n = number of participants with complete data available for each outcome. p value obtained from a two-way mixed ANOVA test. * denotes significant difference, p < 0.05. BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; BPsys, systolic blood pressure; BPdia, diastolic blood pressure.